<DOC>
	<DOCNO>NCT00439426</DOCNO>
	<brief_summary>This single arm study ass efficacy safety Xeloda + oxaliplatin give first line treatment patient metastatic nasopharyngeal cancer . Patients receive Xeloda ( 1000mg/m2 bid orally day 1 day 14 , follow rest period 7 day ) plus oxaliplatin ( 130mg/m2 iv infusion day 1 21 day cycle ) 6-8 cycle . The anticipated time study treatment disease progression , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Xeloda ( Capecitabine ) Combination With XELOX ( Oxaliplatin ) Patients With Metastatic Nasopharyngeal Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>adult patient , 1875 year age ; history nasopharyngeal cancer distant metastasis ; previous chemotherapy past 6 month ; recovery previous radiotherapy ; ability swallow retain oral medication . previous cytotoxic chemotherapy ; radiotherapy within 4 week treatment start ; history another malignancy within last 5 year ; clinically significant cardiac disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>